Surgical Versus Medical Treatment for Diabetic Macular Edema: A Review
Medical hypothesis discovery and innovation in ophthalmology,
Vol. 6 No. 4 (2017),
1 December 2017
,
Page 136-143
Abstract
We aimed to compare the results of pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling, an alternative therapeutic strategy, with those of medical treatment for chronic macular edema. We conducted a review of the literature on the microscopic, anatomical, and functional reasons for performing PPV with ILM peeling in patients with diabetic macular edema (DME). We searched the PubMed database for articles published between 2000 and 2017. We used the medical subject heading vitrectomy diabetic macular edema and the keywords diabetic macular edema, internal limiting membrane peeling, pars plana vitrectomy, diabetic retinopathy, and optical coherence tomography. Analysis of the literature revealed that cytokines, vascular endothelial growth factor, reactive oxygen species (ROS), and advanced glycation end-products (AGEs) play a unique role in DME. The vitreous cavity serves as a physiological reservoir for all inflammatory molecules. AGE receptors are localized at the footplates of Muller cells and the external limiting membrane (ELM). The footplates of Muller cells are in contact with the ILM, which suggests that they might be responsible for the structural damage (i.e., thickening) observed in the ILM of patients with DME. Therefore, PPV could allow a reduction of cytokines and pro-inflammatory molecules from the vitreous cavity. ILM peeling could eliminate not only the physical traction of a thickened structure, but also the natural reservoir of AGEs, ROS, and inflammatory molecules. PPV with ILM peeling is a surgical option that should be considered when treating patients with chronic DME.References
Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116(3):497-503. doi: 10.1016/j.ophtha.2008.10.016 pmid: 19167079
WHO. Global Report on Diabetes: World Health Organization; 2016 [cited 2017]. Available from: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?ua=1.
Romero-Aroca P, de la Riva-Fernandez S, Valls-Mateu A, Sagarra-Alamo R, Moreno-Ribas A, Soler N, et al. Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up. BMC Ophthalmol. 2016;16:136. doi: 10.1186/s12886-016-0318-x pmid: 27491545
Burke SJ, Karlstad MD, Eder AE, Regal KM, Lu D, Burk DH, et al. Pancreatic beta-Cell production of CXCR3 ligands precedes diabetes onset. Biofactors. 2016;42(6):703-15. doi: 10.1002/biof.1304 pmid: 27325565
Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1-32. doi: 10.1016/j.survoph thal.2008.10.001 pmid: 19171208
Koskela UE, Kuusisto SM, Nissinen AE, Savolainen MJ, Liinamaa MJ. High vitreous concentration of IL-6 and IL-8, but not of adhesion molecules in relation to plasma concentrations in proliferative diabetic retinopathy. Ophthalmic Res. 2013;49(2):108-14. doi: 10.1159/000342977 pmid: 23257933
Mishra S, Mishra BB. Study of Lipid Peroxidation, Nitric Oxide End Product, and Trace Element Status in Type 2 Diabetes Mellitus with and without Complications. Int J Appl Basic Med Res. 2017;7(2):88-93. doi: 10.4103/2229-516X.205813 pmid: 28584737
Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653-64. pmid: 12941734
Ciulla TA, Harris A, Latkany P, Piper HC, Arend O, Garzozi H, et al. Ocular perfusion abnormalities in diabetes. Acta Ophthalmol Scand. 2002;80(5):468-77. pmid: 12390156
Paget C, Lecomte M, Ruggiero D, Wiernsperger N, Lagarde M. Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced glycation end products. Free Radic Biol Med. 1998;25(1):121-9. pmid: 9655530
Duh E, Aiello LP. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes. 1999;48(10):1899-906. pmid: 10512352
Bazzoni G. Endothelial tight junctions: permeable barriers of the vessel wall. Thromb Haemost. 2006;95(1):36-42. pmid: 16543959
Deissler HL, Deissler H, Lang GE. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells. Br J Ophthalmol. 2011;95(8):1151-6. doi: 10.1136/bjo.2010.192229 pmid: 21273213
Gonzalez-Salinas R, Garcia-Gutierrez MC, Garcia-Aguirre G, Morales-Canton V, Velez-Montoya R, Soberon-Ventura VR, et al. Evaluation of VEGF gene polymorphisms and proliferative diabetic retinopathy in Mexican population. Int J Ophthalmol. 2017;10(1):135-9. doi: 10.18240/ijo.2017.01.22 pmid: 28149790
Kawashima H, Mizukawa K, Kiryu J. Factors associated with visual recovery after sub-Tenon injection of triamcinolone acetonide in diabetic macular edema. Clin Ophthalmol. 2012;6:1307-14. doi: 10.2147/OPTH .S34631 pmid: 22927745
Kim BY, Smith SD, Kaiser PK. Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol. 2006;142(3):405-12. doi: 10.1016/j.ajo .2006.04.023 pmid: 16935584
Sambhav K, Grover S, Chalam KV. The application of optical coherence tomography angiography in retinal diseases. Surv Ophthalmol. 2017;62(6):838-66. doi: 10.1016/j.survophthal.2017.05.006 pmid: 28579550
Matsunaga DR, Yi JJ, De Koo LO, Ameri H, Puliafito CA, Kashani AH. Optical Coherence Tomography Angiography of Diabetic Retinopathy in Human Subjects. Ophthalmic Surg Lasers Imaging Retina. 2015;46(8):796-805. doi: 10.3928/23258160-201509 09-03 pmid: 26431294
Diabetic Retinopathy Clinical Research N, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860-7. doi: 10.1016/ j.ophtha.2007.05.062 pmid: 17698196
Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399-405. doi: 10.2337/dc10-0493 pmid: 20980427
Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-25. doi: 10.1016/j. ophtha.2011.01.031 pmid: 21459215
Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801. doi: 10.1016/j.ophtha.2011.12.039 pmid: 22330964
Arevalo JF, Lasave AF, Wu L, Acon D, Farah ME, Gallego-Pinazo R, et al. Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group. Br J Ophthalmol. 2016;100(12):1605-10. doi: 10.1136/bjo phthalmol-2015-307950 pmid: 26912377
Haller JA, Bandello F, Belfort R, Jr., Blumenkranz MS, Gillies M, Heier J, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-46 e3. doi: 10.1016/j.ophtha.2010.03.032 pmid: 20417567
EMC. Ozurdex Summary of Product Characteristics: EMC; 2017 [cited 2017].
London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther. 2011;28(5):351-66. doi: 10.1007/s12325-011-0019-z pmid: 21494891
Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(1):80-6. doi: 10.1167/iovs.10-5285 pmid: 20702826
Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 2013;120(9):1843-51. doi: 10.1016/ j.ophtha.2013.02.018 pmid: 23706947
Boyer DS, Yoon YH, Belfort R, Jr., Bandello F, Maturi RK, Augustin AJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904-14. doi: 10.1016/ j.ophtha.2014.04.024 pmid: 24907062
Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121(12):2473-81. doi: 10.1016/j.ophtha.2014.07.002 pmid: 25155371
Mastropasqua R, Toto L, Borrelli E, Di Antonio L, De Nicola C, Mastrocola A, et al. Morphology and Function over a One-Year Follow Up Period after Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema. PLoS One. 2015;10(12):e0145663. doi: 10.1371/journal.pone.01 45663 pmid: 26720268
Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-7. doi: 10.1056/NEJM19941201 3312203 pmid: 7526212
Augustin AJ, Keller A, Koch F, Jurklies B, Dick B. [Effect of retinal coagulation status on oxidative metabolite and VEGF in 208 patients with proliferative diabetic retinopathy]. Klin Monbl Augenheilkd. 2001;218(2):89-94. doi: 10.1055/s-2001-12251 pmid: 11258131
Stefansson E. Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol. 2006;51(4):364-80. doi: 10.1016/j.survophthal.2006.0 4.005 pmid: 16818083
Holekamp NM, Shui YB, Beebe DC. Vitrectomy surgery increases oxygen exposure to the lens: a possible mechanism for nuclear cataract formation. Am J Ophthalmol. 2005;139(2):302-10. doi: 10.1016/j.ajo.2004.09.046 pmid: 15733992
Tamura K, Yokoyama T, Ebihara N, Murakami A. Histopathologic analysis of the internal limiting membrane surgically peeled from eyes with diffuse diabetic macular edema. Jpn J Ophthalmol. 2012;56(3):280-7. doi: 10.1007/s10384-012-0130-y pmid: 22438196
Yanyali A, Bozkurt KT, Macin A, Horozoglu F, Nohutcu AF. Quantitative assessment of photoreceptor layer in eyes with resolved edema after pars plana vitrectomy with internal limiting membrane removal for diabetic macular edema. Ophthalmologica. 2011;226(2):57-63. doi: 10.1159/000327597 pmid: 21555906
Sakamoto A, Nishijima K, Kita M, Oh H, Tsujikawa A, Yoshimura N. Association between foveal photoreceptor status and visual acuity after resolution of diabetic macular edema by pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol. 2009;247(10):1325-30. doi: 10.1007/s00417-009-1107-5 pmid: 19430805
Otani T, Yamaguchi Y, Kishi S. Correlation between visual acuity and foveal microstructural changes in diabetic macular edema. Retina. 2010;30(5):774-80. doi: 10.1097/IAE.0b013e3181c2e0d6 pmid: 19996821
Yamada Y, Suzuma K, Ryu M, Tsuiki E, Fujikawa A, Kitaoka T. Systemic factors influence the prognosis of diabetic macular edema after pars plana vitrectomy with internal limiting membrane peeling. Curr Eye Res. 2013;38(12):1261-5. doi: 10.3109/02713683.2013.820327 pmid: 23972000
Chhablani JK, Kim JS, Cheng L, Kozak I, Freeman W. External limiting membrane as a predictor of visual improvement in diabetic macular edema after pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol. 2012;250(10):1415-20. doi: 10.1007/s00417-012-1968-x pmid: 22354371
Romano MR, Romano V, Vallejo-Garcia JL, Vinciguerra R, Romano M, Cereda M, et al. Macular hypotrophy after internal limiting membrane removal for diabetic macular edema. Retina. 2014;34(6):1182-9. doi: 10.1097/IAE.0000000000000076 pmid: 24846134
Ichiyama Y, Sawada O, Mori T, Fujikawa M, Kawamura H, Ohji M. The effectiveness of vitrectomy for diffuse diabetic macular edema may depend on its preoperative optical coherence tomography pattern. Graefes Arch Clin Exp Ophthalmol. 2016;254(8):1545-51. doi: 10.1007/s00417-015-3251-4 pmid: 26780461
Kumagai K, Ogino N, Furukawa M, Demizu S, Atsumi K, Kurihara H, et al. [Internal limiting membrane peeling in vitreous surgery for diabetic macular edema]. Nippon Ganka Gakkai Zasshi. 2002;106(9):590-4. pmid: 12385125
Kumagai K, Hangai M, Ogino N, Larson E. Effect of Internal Limiting Membrane Peeling on Long-Term Visual Outcomes for Diabetic Macular Edema. Retina. 2015;35(7):1422-8. doi: 10.1097/IAE.000000000000 0497 pmid: 26102439
Bonnin S, Sandali O, Bonnel S, Monin C, El Sanharawi M. VITRECTOMY WITH INTERNAL LIMITING MEMBRANE PEELING FOR TRACTIONAL AND NONTRACTIONAL DIABETIC MACULAR EDEMA: Long-term Results of a Comparative Study. Retina. 2015;35(5):921-8. doi: 10.1097/IAE.0000000000000 433 pmid: 25545486
Nizawa T, Arai M, Takatsuna Y, Oshitari T, Sato E, Yamamoto S. [Comparison of visual acuity and central macular thickness after vitrectomy for diffuse diabetic macular edema with or without preoperative treatments]. Nippon Ganka Gakkai Zasshi. 2013;117(10):785-92. pmid: 24354262
Diabetic Retinopathy Clinical Research Network Writing C, Haller JA, Qin H, Apte RS, Beck RR, Bressler NM, et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010;117(6):1087-93 e3. doi: 10.1016/j.ophtha.2009.10.040 pmid: 20299105
Jackson TL, Nicod E, Angelis A, Grimaccia F, Pringle E, Kanavos P. PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA: A Systematic Review, Meta-Analysis, and Synthesis of Safety Literature. Retina. 2017;37(5):886-95. doi: 10.1097/IAE.0000000000 001280 pmid: 27632713
- Abstract Viewed: 1624 times
- Full Text PDF Downloaded: 1316 times